Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The pharmacokinetics of ketamine in analgesic doses after intravenous, intramuscular, and oral administration was investigated in healthy volunteers. Plasma ketamine concentration-time curves were fitted by a two-compartment open model with a terminal half-life of 186 min. Absorption after intramuscular injection was rapid and the bioavailability was 93%. However, only 17% of an oral dose was absorbed because of extensive first-pass metabolism. Simultaneous measurements of the elevation of pain threshold in an ischemic exercise test showed a marked effect for 15-60 min after intramuscular injection, but little or no effect after the oral solution. Pain threshold elevation occurred at plasma ketamine concentrations above 160 ng/ml.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding elimination of ketamine and its metabolites, the elimination half-life is between two to four hours, varying slightly with the route of administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Clements et al., 1982
Citations
Cites
A Simplex Method for Function Minimization
Nelder, J. A., & Mead, R. (1965) · The Computer Journal · doi:10.1093/comjnl/7.4.308 · Cited by 28,905
TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. II
DURBIN, J., & WATSON, G. S. (1951) · Biometrika · doi:10.1093/biomet/38.1-2.159 · Cited by 3,619
Drugs and the Pharmaceutical Sciences
(2010) · Drugs and the pharmaceutical sciences · doi:10.1201/ihcdruphasci · Cited by 586
New Method for Calculating the Intrinsic Absorption Rate of Drugs
Loo, J. C. K., & Riegelman, S. (1968) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600570602 · Cited by 466
PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE
GRANT, I. S., NIMMO, W. S., & CLEMENTS, J. A. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.8.805 · Cited by 355
Self-citationPHARMACOKINETICS AND ANALGESIC EFFECT OF KETAMINE IN MAN
CLEMENTS, J. A., & NIMMO, W. S. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.1.27 · Cited by 322
Self-citationKETAMINE INFUSIONS: PHARMACOKINETICS AND CLINICAL EFFECTS
IDVALL, J., AHLGREN, I., ARONSEN, K. F., & STENBERG, P. (1979) · British Journal of Anaesthesia · doi:10.1093/bja/51.12.1167 · Cited by 306
Influence of Route of Administration on Drug Availability
Rowland, M. (1972) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600610111 · Cited by 264
Pedersen, P. V. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061732 · Cited by 219
Ottaway, J. H. (1973) · Biochemical Journal · doi:10.1042/bj1340729 · Cited by 101
Research works printed but not linked: 9
- Wieber, 1975, Anaesthetist, 24, 260
- Clausen, 1975, Med. J., 49, 1437
- Harrison, 1943, Proc. Assoc. Res. Nerv. Ment. Dis., 23, 154
- Walle, 1970, Acta Pharm. Suec., 7, 389
- Durbin, 1950, Biometrika, 37, 409
- Gibaldi, 1979, Vol. 1, 232
- Rowland, 1972, ibid, 61, 70
- Gibaldi, 1971, ibid., 60, 624
- Pang, 1978, ibid., 67, 703
Cited by
Items 201–300 of 418
In Vitro and In Vivo Effects of Ketamine on Generation and Function of Dendritic Cells
Zeng, J., Xia, S.-X., Zhong, W., Li, J., & Lin, L. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11113fp · Cited by 12
Wang, X., Xie, H., & Wang, G. (2006) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2006.03.023 · Cited by 12
“The plasma concentrations of ketamine in the present study may well have had analgesic effects because the effective plasma concentration of ketamine in elevating pain threshold is 150 ng/mL [32].”
BackgroundChong, C., & Schug, S. A. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01066-x · Cited by 12
Lu, Y., Li, Q., Wang, Y., Zhou, Z., Zhang, D., Bao, Y., Wu, J., & Cui, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.816995 · Cited by 15
“Due to the extensive first-pass elimination effect, only 17% of an oral dose is absorbed (Clements et al., 1982).”
BackgroundJiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 15
“With i.v. infusion in human patients, the peak plasma concentration of ketamine can reach as high as 1–1.5 μM [102,133,198], which is sufficient to at least partially inhibit or activate these other molecular targets.”
BackgroundInfluentialMukhaizeem, S. A., Nasa, A., Waldron, D., McDaid, A., Gorman, P., Featherstone, M., Barry, M., Murphy, P. M., Gallagher, H., Nair, S., et al. (2023) · Frontiers in Pain Research · doi:10.3389/fpain.2023.1268985 · Cited by 12
“As such, it has a low oral bioavailability, estimated at 10% – 20% (20).”
BackgroundUsing Ketamine to Model Semantic Deficits in Schizophrenia
Neill, E., Rossell, S. L., McDonald, S., Joshua, N. R., Jansen, N., & Morgan, C. J. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318234ee1e · Cited by 11
“The program uses a bolus eliminationtransfer infusion scheme based on the pharmacokinetic model of Clements et al.41 A steady state of predicted plasma ketamine/ placebo concentration according to the model was achieved in a period of 10 minutes.”
MethodReıslı, R., Çelik, J. B., Tuncer, S., Yosunkaya, A., & Otelcioğlu, Ş. (2005) · European Journal of Anaesthesiology · doi:10.1017/s026502150300005x · Cited by 11
Buerge, M., Kratzer, S., Mattusch, C., Hofmann, C., Kreuzer, M., Parsons, C. G., & Rammes, G. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.031 · Cited by 14
Antidepressants enter cells, organelles, and membranes
Blumenfeld, Z., Bera, K., Ċastrén, E., & Lester, H. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01725-x · Cited by 15
“Intramuscular (IM) injections have high bioavailability in adults [108] but present similar structural barriers as the IV route, and oral administration achieves a bioavailability of only 24% [89] due to the aforementioned ef fi cient lever metabolism [96].”
BackgroundA review of the clinical applications of ketamine in pediatric oncology
Prakash, S., Gupta, A., Meena, J. P., & Seth, R. K. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28785 · Cited by 11
Nociception-specific blink reflex: pharmacology in healthy volunteers
Marin, J., Gantenbein, A. R., Paemeleire, K., Kaube, H., & Goadsby, P. J. (2015) · The Journal of Headache and Pain · doi:10.1186/s10194-015-0568-7 · Cited by 12
Liu, Q., Xu, T., Zhang, Z.-B., Leung, C., You, D., Wang, S.-W., Yi, S., Jing, Q., Xie, R., Li, H.-J., et al. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.04.018 · Cited by 10
Non-narcotic Modalities for the Management of Acute Pain
Lee, V. C. (1990) · Critical Care Clinics · doi:10.1016/s0749-0704(18)30384-1 · Cited by 11
Ketamine for Complex Regional Pain Syndrome
Lii, T. R., & Singh, V. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.03.005 · Cited by 10
A systematic review of the use of peri-operative systemic ketamine in cats and dogs for analgesia
Wickstead, F., & Martinez, M. (2025) · The Veterinary Journal · doi:10.1016/j.tvjl.2025.106350 · Cited by 14
Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets
Munguba, H., Arefin, A., Hasegawa, R., Posa, L., Romano, G. R., Peddada, T., Donatelle, A., Singh, A., Gutzeit, V. A., Vijay, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.04.006 · Cited by 12
Oral dexmedetomidine for preoperative sedation in an adult uncooperative autistic patient
Konia, M. R. (2016) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2016.03.037 · Cited by 9
Mostafa, R. H., Khamis, A. M., Saleh, A. N., Mekki, Y. M. H., Kamal, M. M., Ibrahim, I. M., & Ismaiel, M. A. A. (2021) · Anesthesiology Research and Practice · doi:10.1155/2021/6674658 · Cited by 12
“Interestingly, the half-life of ketamine is only 3 hours, suggesting that its antidepressant effect is unrelated to continuous blocking of N-methyl-d-aspartate (NMDA) receptors [8].”
BackgroundRegnier, S. D., Lile, J. A., Rush, C. R., & Stoops, W. W. (2022) · Journal of the Experimental Analysis of Behavior · doi:10.1002/jeab.744 · Cited by 10
General anaesthesia with remifentanil and cisatracurium for a superobese patient
Gaszynski, T. M., Gaszyński, W., & Strzelczyk, J. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503250134 · Cited by 9
Ketamine in Substance Use Disorder Treatment: A Narrative Review
Famuła, A., Radoszewski, J., Czerwiec, T., Sobiś, J., & Więckiewicz, G. (2024) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2024.241522 · Cited by 10
Mikellides, G. (2025) · Psychoactives · doi:10.3390/psychoactives4030020 · Cited by 9
“Intravenous ketamine achieves approximately 100% bioavailability, while intramuscular administration yields about 93%, ensuring stable plasma concentrations and facilitating reliable clinical responses, particularly in controlled treatment settings [19].”
EFFICACY AND SAFETY OF ORAL KETAMINE PREMEDICATION IN CHILDREN UNDERGOING DAY CASE SURGERY.
Oyedepo, O. O., Nasir, A. A., Abdur-Rahman, L., Kolawole, I. K., Bolaji, B., & Ige, O. A. (2016) · PubMed Central · Cited by 8
Amr, M., Shams, T., & Al-Wadani, H. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003231 · Cited by 10
Raymondos, K., Münte, S., Krauß, T., Grouven, U., & Piepenbrock, S. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000085 · Cited by 8
Stereoselective Pharmacokinetics of Ketamine Administered at a Low Dose in Awake Dogs
Pargätzi, G., Bergadano, A., Spadavecchia, C., Theurillat, R., Thormann, W., & Levionnois, O. (2024) · Animals · doi:10.3390/ani14071012 · Cited by 9
“The intravenous dosage recommended in the veterinary literature ranges between 0.002 and 0.017 mg/kg/min [12–14], which seems adequate to minimize undesired effects [15–17].”
BackgroundInfluentialInduction of Anaesthesia in the Home
Chan, W. P., & Chilvers, C. R. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000617 · Cited by 7
Ketamine potentiates TRPV1 receptor signaling in the peripheral nociceptive pathways
da Costa, F. L. P., Pinto, M. C. X., Santos, D. C., Carobin, N. V., de Jesus, I. C. G., Ferreira, L. A., Guatimosim, S., da Silva, J. F., & de Castro, C. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114210 · Cited by 7
Pérez‐Pereira, A., Maia, A. S., Gonçalves, V. M. F., Ribeiro, C. M. R., & Tiritan, M. E. (2021) · Chemosensors · doi:10.3390/chemosensors9090242 · Cited by 7
Ogawa-Okamoto, C., Saito, S., Nishihara, F., Yuki, N., & Goto, F. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503210139 · Cited by 7
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 9
Krenz, J. R., Medeiros, K., & Lupez, K. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.03.058 · Cited by 6
Targeting Affective Mood Disorders With Ketamine to Prevent Chronic Postsurgical Pain
Willis, D. E., & Goldstein, P. A. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.872696 · Cited by 7
An overview of emergency pharmacotherapy for priapism
Bobo, G. A., Almajed, W., Conlon, J., Morenas, R., & Hellstrom, W. J. G. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2099271 · Cited by 6
Ketamine Promotes Adaption-Induced Orientation Plasticity and Vigorous Network
Ouelhazi, A., Lussiez, R., & Molotchnikoff, S. (2022) · Brain Research · doi:10.1016/j.brainres.2022.148111 · Cited by 7
Haloperidol for the Treatment of Ketamine-Indu ced Emergence Delirium
Atlas, G. M., & Milles, M. (2007) · Journal of Anaesthesiology Clinical Pharmacology · Cited by 6
Santamaria, R., Pailleux, F., & Beaudry, F. (2014) · Biomedical Chromatography · doi:10.1002/bmc.3199 · Cited by 8
“However, in all species, total clearance observed is relatively high but the terminal half-life is longer in human compared with rodents (Clements et al., 1982; Veilleux-Lemieux et al., 2012).”
BackgroundKetamine and Depression: A Review
Ryan, W. C., Marta, C. J., & Koek, R. J. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.40 · Cited by 6
Haltiavaara, K. M., Laitinen, J. O., Kaukinen, S., Viljakka, T., Laippala, P. J., & Luukkaala, T. H. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503220135 · Cited by 6
Levinstein, M. R., Schoenborn, I., Manza, P., Schatzberg, A. F., Zarate, C. A., Bonaventura, J., & Michaelides, M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.021 · Cited by 6
Sim, J., Kyung, S. Y., Jo, J., Choi, H., Jeong, S., Lee, N.-H., & Kim, S. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124720 · Cited by 8
Huang, H.-C., Huang, S., Yu, K.-H., Wang, J.-H., & Wu, J.-T. (2017) · Veterinary Anaesthesia and Analgesia · doi:10.1016/j.vaa.2017.03.003 · Cited by 5
Ketamine. A 50-year modern history
Диасамидзе, К. Э., Мишин, Г. М., Читорелидзе, М. А., & Абаджян, М. Ф. (2021) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology202105186 · Cited by 5
Wittkugel, E. P., & Samol, N. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34125-7.00052-8 · Cited by 5
A Broadly Applicable Diels–Alder-Based Synthesis of Ketamine-Related Arylcyclohexylamines
Weber, H., Drouvé, N., Kortenbrede, L., & Sheikh, S. E. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01226 · Cited by 6
Human pharmacokinetics of analgesics and methods for their determination in biological fluids
Miskolczi, P., & Vereczkey, L. (1985) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(85)80026-1 · Cited by 5
Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling
Stoeva, S., Hvarchanova, N., Gancheva, S., Eftimov, M., Georgiev, K., & Radeva-Ilieva, M. P. (2025) · Metabolites · doi:10.3390/metabo15110745 · Cited by 7
Bawany, M. H., & Motov, S. M. (2022) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.22.326 · Cited by 4
“When taken PO, ketamine is approximately 20% bioavailable compared to 100% in IV administration.(24) No studies examined the use of intranasal ketamine for VOC, perhaps due to the numerous patient factors that can affect bioavailability in this route, which has been shown to range from 25% to 50%.”
BackgroundSajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 10
“IM ketamine has 93% bioavailability in adult humans and a plasma half-life similar to IV [62, 63], whereas IN S-ketamine is about 50% bioavailable [64 – 66].”
Wegner, G. R. M., Wegner, B. F. M., Cumming, H., de Oliveira, H. G., Campos, L. R., da Silva, L. H. D., Ferreira, C. H. O., Miranda, A. M., Donato, A. B., & do Nascimento, T. S. (2025) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2025.111903 · Cited by 4
Qureshi, M. M., Silman, D., Gadelrab, R., Stein, H., Carmellini, P., Duncan, G., Mehta, M. A., Young, A. H., Reilly, C., & Juruena, M. F. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251340925 · Cited by 4
Oral and Intranasal Ketamine Use in Treatment-Resistant Catatonia: A Clinical Case Report
Gregor, E., & Zheng, W. (2023) · American Journal of Case Reports · doi:10.12659/ajcr.939530 · Cited by 11
“Ketamine has low oral bioavailability (17%) [17].”
Paraphimosis Pain Treatment with Nebulized Ketamine in the Emergency Department
Parraga, C. B., Peng, Y., Cen, E., Dove, D., Fassassi, C., Davis, A., Drapkin, J., Hossain, R., Mahl, E., & Motov, S. M. (2022) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.12.011 · Cited by 4
Ketamine in treatment-resistant depression
Lapidus, K. A. B., & Mathew, S. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.027 · Cited by 4
Utilización de ketamina en el tratamiento del dolor agudo y crónico
López‐Millán, J. M., & Sánchez-Blanco, C. (2007) · Revista de la Sociedad Española del Dolor · Cited by 26
Finnegan, M., Ryan, K. M., Shanahan, E., Harkin, A., Daly, L., & McLoughlin, D. M. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0080-0 · Cited by 5
“Bioavailability of ketamine is highest when administered intravenously [23].”
BackgroundExperimental Therapies for Treatment-Resistant Depression
Jha, M., & Trivedi, M. (2018) · Focus · doi:10.1176/appi.focus.20180013 · Cited by 6
Ketamine-induced bladder dysfunction
Hardaker, H. (2012) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 4
Serna, A. V. (1998) · Anales de Pediatría · Cited by 4
Antidepressant-Like Effects of Ketamine on Fear Conditioning and Extinction
Kulyk, B. D. (2017) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 4
Non-narcotic Modalities for the Management of Acute Pain
Lee, V. C. (1989) · Anesthesiology Clinics of North America · doi:10.1016/s0889-8537(21)00225-x · Cited by 4
MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses
Piazza, M. K., Weit, A. R., Kavalali, E. T., Neul, J. L., & Monteggia, L. M. (2025) · iScience · doi:10.1016/j.isci.2025.112485 · Cited by 3
“It is important to note that the behavioral action of ketamine lasts far longer than its short half-life, 67 suggesting that ketamine generates compounding changes that propagate its sustained action.”
Zhou, Y., Chen, G., & Zhu, Y. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70500 · Cited by 3
“However, human pharmacokinetic data indicate that plasma concentrations during anesthesia typically range from 2 to 10 μM, with the potential for higher tissue concentrations due to local accumulation [36].”
Pharmacokinetics and Pharmacodynamics in the Pediatric Population
Anderson, B. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1390-9_11 · Cited by 3
Shanthanna, H. (2012) · InTech eBooks · doi:10.5772/36882 · Cited by 3
Recreational Use of Ketamine and Its Interaction with NMDA Receptors
Félix, L. M., Antunes, L. M., Campos, S., Venâncio, C. A. S., & Coimbra, A. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00062-5 · Cited by 3
Weinbroum, A. A. (2018) · Journal of Anesthesia & Clinical Research · doi:10.4172/2155-6148.1000827 · Cited by 3
“Ketamine absorption after intramuscular injection has been described as more rapid, with a bioavailability of 93% [81].”
BackgroundPharmacokinetics and Pharmacodynamics in the Pediatric Patient
Anderson, B. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47609-4_25 · Cited by 3
Ding, J., Yu, Y., Luo, M., Fang, X., Tan, D., Qin, H., Ren, X., Zhang, Y., Luo, T., Chen, L., et al. (2023) · Ibrain · doi:10.1002/ibra.12104 · Cited by 2
“6 9 These reactions further limit ketamine's application in clinical practice.”
Maxwell, G. M. (1984) · Springer eBooks · doi:10.1007/978-1-4684-7544-9_6 · Cited by 3
The Effect of Ketamine on Configural Facial Processing
Neill, E., Joshua, N. R., Morgan, C. J. A., & Rossell, S. L. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000278 · Cited by 3
“The program uses a bolus elimination–transfer infusion scheme on the basis of the Clements pharmacokinetic model.(31) A steady state of predicted plasma ketamine/placebo concentration according to the modelwas achieved in a period of 10minutes.”
MethodElo, J. A., & Sun, H.-H. B. (2016) · InTech eBooks · doi:10.5772/63539 · Cited by 4
“Ketamine's expected effects are excellent analgesia [27], strong anterograde amnesia, pre‐ served laryngeal reflexes, suppression of convulsive neuronal activities, increased intraocular and intracranial pressures, and increased salivation and lacrimation.”
BackgroundCampbell, A. E., Turley, A., Wilkes, A. R., & Hall, J. E. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000097 · Cited by 3
Essentials of Disaster Anesthesia
McQueen, K., & Kucik, C. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316181454 · Cited by 4
Njau, S. N., Zavaliangos‐Petropulu, A., Joshi, S. H., Brooks, J. O., O'Neill, J., Roger, W. P., Norris, V., Espinoza, R. T., & Narr, K. L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70102 · Cited by 2
“Also, ketamine has a short elimination half-life of 2–3 h in humans (Clements and Nimmo 1981; Clements et al. 1982).”
Le, G. H., & McIntyre, R. S. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2619757 · Cited by 4
“The hydrophobic pocket potentially explains the emergence of antidepressant effects at plasma concentrations (~0.3–0.78 µM ketamine) below the 5–10 µM required to saturate the pore and induce dissociative anesthetic effects [31,88–90].”
InfluentialPharmakokinetik von Medikamenten durch Echtzeit‐Analyse der Atemluft von Mäusen
Li, X., Sinues, P., Dallmann, R., Bregy, L., Hollmén, M., Proulx, S. T., Brown, S. A., Detmar, M. J., Kohler, M., & Zenobi, R. (2015) · Angewandte Chemie · doi:10.1002/ange.201503312 · Cited by 2
The frequency of polidrug use in a driving population in Rome
Lagravinese, G. M., Mammone, A., Rossi, C. R., Vita, M. D., Marino, V., Feola, A., & Marsella, L. (2022) · Epidemiology Biostatistics and Public Health · doi:10.2427/11179 · Cited by 4
“Giovanni Michele Lagravinese((1)), Alessia Mammone((2)), Carla Rossi((2)), Miriam De Vita((1)), Valeria Marino((3)), Alessandro Feola((4)), Luigi Tonino Marsella((3))”
BackgroundSajid, S., Lawrence, R. E., Galfalvy, H., Keilp, J. G., Moitra, V. K., Mann, J. J., & Grunebaum, M. F. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100690 · Cited by 2
“In contrast, IM ketamine has a 93 % bioavailability and plasma half-life similar to IV ketamine (Clements et al., 1982; Zanos et al., 2018).”
BackgroundDasari, L. N. S. S., & Ninave, S. S. (2024) · Cureus · doi:10.7759/cureus.67550 · Cited by 6
“This difference in pharmacokinetics significantly impacts the medication’s efficacy [17].”
BackgroundPharmacokinetics of intravenous anesthetics
Servin, F., & Sear, J. W. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781933.028 · Cited by 2
Laryngeal mask airway severed by biting
Heffernan, A. M., White, M., Curran, A., & Colbert, S. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503230131 · Cited by 2
Venyo, A. K. G., & Benatar, B. (2012) · Cited by 2
Neurobiological Augmentation of Psychotherapy in Treatment Resistant Depression
Li, S. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.s2-002 · Cited by 2
S-ketamine for the treatment of depression
Järventausta, K., Kampman, O., Yli‐Hankala, A., & Leinonen, E. V. J. (2015) · Cited by 2
Cartágenes, S. D. C., Fernandes, L. M. P., de Andrade, E. F., Prediger, R. D., & Maia, C. D. S. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805373-7.00032-3 · Cited by 2
Langman, L. J., Bechtel, L. K., & Holstege, C. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00035-4 · Cited by 3
Ketamine: Not Just for Pediatric Sedation?
Reynolds, S. L. (2017) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2017.09.008 · Cited by 2
Chaki, S., & Yamaguchi, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00011-6 · Cited by 2
International Humanitarian Law
Burkle, C. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316181454.021 · Cited by 2
Leslie, E. (2010) · BIROn (Birkbeck, University of London) · Cited by 2
Reply to: Dose- and Exposure-Response to Ketamine in Depression
Murrough, J. W., Gallo, J. M., Collins, K. A., Rot, M. A. H., & Charney, D. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.018 · Cited by 3
Sáenz, M. C., Gálvez, F. E., García, I. A., Alonso, M. B. M., Salvador, A. V., & García-Carricondo, A. R. (2014) · Revista Española de Cirugía Oral y Maxilofacial · doi:10.1016/j.maxilo.2013.11.002 · Cited by 1
Ketamine and Its Pharmacologic Profile in Psychiatric Disorders
Dugar, A., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180314-01 · Cited by 1
Hu, X., Liu, J., Wu, J., Xiong, Z., & Li, N. (2025) · Journal of Analysis and Testing · doi:10.1007/s41664-025-00369-8 · Cited by 2
“This may account for how a single subanesthetic dose of ketamine can exert longer-term antidepressant efficacy that outlasts the duration of ketamine and its metabolites’ half-lives [25, 26].”
Asrar, B., Metin, S., Sen, Z., & Ünal, G. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110650 · Cited by 1
Dhaoui, R., Kouraichi, C., Toumia, M., Ali, K. B. H., Sekma, A., Jaballah, R., Yaakoubi, H., Boukadida, L., Beltaïef, K., Mezgar, Z., et al. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.09.019 · Cited by 1
Strous, J. F. M., Roelandt, G. H. J., van Dalfsen, J. H., Kamphuis, J., Marijnissen, R. M., & Schoevers, R. A. (2025) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70044 · Cited by 1
“%) and most reliable bioavailability (Clements et al. 1982), but poses practical challenges.”
Pak, T. K., Kimatian, S. J., Emslie, G. J., & Ayvaci, E. R. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250040 · Cited by 1
Metadata
- Authors
- Clements, J. A., Nimmo, W. S., & Grant, I. S.
- Affiliations
- Heriot-Watt University (GB)
- Western Infirmary (GB)
- Corresponding author
- Clements, J.A.
- ORCID
- Grant, I.S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 1982-05
- Volume
- 71
- Issue
- 5
- Pages
- 539-542
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2094496261
- Cited by
- 420
- References
- 20
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 17 · 2023: 20 · 2022: 34 · 2021: 17 · 2020: 50 · 2019: 11 · 2018: 20 · 2017: 13 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 16 · 2012: 10
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- ketamine, pharmacokinetics, bioavailability, analgesia, pain threshold, first-pass metabolism, intramuscular injection, oral administration, intravenous administration, two-compartment model, terminal half-life
- MeSH terms
- Administration, Oral, Adult, Analgesics, Biological Availability, Physical Exertion, Humans, Injections, Intramuscular, Injections, Intravenous, Ketamine, Kinetics, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.